Biologics Market Transparency Act of 2022

12/29/2022, 4:48 PM

Congressional Summary of S 4302

Biologics Market Transparency Act of 2022

This bill requires biologics manufacturers to notify the Food and Drug Administration in advance of withdrawing a product from sale.

Current Status of Bill S 4302

Bill S 4302 is currently in the status of Bill Introduced since May 25, 2022. Bill S 4302 was introduced during Congress 117 and was introduced to the Senate on May 25, 2022.  Bill S 4302's most recent activity was Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S2709) as of May 25, 2022

Bipartisan Support of Bill S 4302

Total Number of Sponsors
1
Democrat Sponsors
1
Republican Sponsors
0
Unaffiliated Sponsors
0
Total Number of Cosponsors
3
Democrat Cosponsors
1
Republican Cosponsors
2
Unaffiliated Cosponsors
0

Policy Area and Potential Impact of Bill S 4302

Primary Policy Focus

Health

Alternate Title(s) of Bill S 4302

Biologics Market Transparency Act of 2022Biologics Market Transparency Act of 2022A bill to amend the Federal Food, Drug, and Cosmetic Act to require prompt reports of marketing status by holders of approved applications for biological products, and for other purposes.
Start holding our government accountable!

Comments